🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 8 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 29/12/1992 | 5,25 | 5,25 | 5,13 | 5,13 | -2,38% | 2,38% | 42.400 |
| 28/12/1992 | 5,13 | 5,25 | 5,13 | 5,25 | -2,33% | 2,44% | 40.000 |
| 24/12/1992 | 5,13 | 5,38 | 5,13 | 5,38 | +0,00% | 4,88% | 18.200 |
| 23/12/1992 | 5,63 | 5,63 | 5,13 | 5,38 | -2,27% | 8,89% | 84.600 |
| 22/12/1992 | 5,50 | 5,75 | 5,50 | 5,50 | +0,00% | 4,55% | 197.000 |
| 21/12/1992 | 5,50 | 5,63 | 5,50 | 5,50 | -4,35% | 2,27% | 42.400 |
| 18/12/1992 | 5,50 | 5,75 | 5,50 | 5,75 | +2,22% | 4,55% | 12.200 |
| 17/12/1992 | 5,75 | 5,75 | 5,50 | 5,63 | +0,00% | 4,35% | 53.400 |
| 16/12/1992 | 5,63 | 5,69 | 5,63 | 5,63 | +0,00% | 1,11% | 55.200 |
| 15/12/1992 | 5,69 | 5,75 | 5,63 | 5,63 | +0,00% | 2,20% | 14.000 |
| 14/12/1992 | 6,00 | 6,00 | 5,63 | 5,63 | -2,17% | 6,25% | 168.800 |
| 11/12/1992 | 6,00 | 6,00 | 5,63 | 5,75 | +2,22% | 6,25% | 52.000 |
| 10/12/1992 | 5,63 | 5,88 | 5,63 | 5,63 | +0,00% | 4,44% | 18.800 |
| 09/12/1992 | 5,63 | 5,88 | 5,63 | 5,63 | -4,26% | 4,44% | 120.000 |
| 08/12/1992 | 5,63 | 5,88 | 5,63 | 5,88 | +4,44% | 4,44% | 36.400 |
| 07/12/1992 | 5,88 | 5,88 | 5,50 | 5,63 | +2,27% | 6,38% | 70.800 |
| 04/12/1992 | 5,88 | 5,88 | 5,50 | 5,50 | -6,38% | 6,38% | 13.400 |
| 03/12/1992 | 5,50 | 5,88 | 5,50 | 5,88 | +5,62% | 6,82% | 18.000 |
| 02/12/1992 | 5,38 | 5,63 | 5,38 | 5,56 | +1,14% | 4,65% | 19.000 |
| 01/12/1992 | 5,63 | 5,63 | 5,38 | 5,50 | -2,22% | 4,44% | 277.000 |
| 30/11/1992 | 5,38 | 5,63 | 5,38 | 5,63 | +2,27% | 4,65% | 47.000 |
| 27/11/1992 | 5,63 | 5,63 | 5,50 | 5,50 | +0,00% | 2,22% | 4.200 |
| 25/11/1992 | 5,38 | 5,63 | 5,38 | 5,50 | +2,33% | 4,65% | 9.200 |
| 24/11/1992 | 5,63 | 5,63 | 5,38 | 5,38 | -4,44% | 4,44% | 6.600 |
| 23/11/1992 | 5,50 | 5,88 | 5,38 | 5,63 | -1,10% | 9,09% | 436.200 |
| 20/11/1992 | 5,88 | 6,13 | 5,69 | 5,69 | -3,19% | 7,45% | 84.200 |
| 19/11/1992 | 6,25 | 6,25 | 5,88 | 5,88 | -6,00% | 6,00% | 22.400 |
| 18/11/1992 | 6,25 | 6,25 | 5,88 | 6,25 | +0,00% | 6,00% | 4.200 |
| 17/11/1992 | 6,38 | 6,38 | 6,13 | 6,25 | -1,96% | 3,92% | 51.200 |
| 16/11/1992 | 6,13 | 6,38 | 6,00 | 6,38 | +6,25% | 6,12% | 75.000 |